TICKERNERD
Menu
TYRATYRAHealthcare · Biotechnology

TYRA Stock Forecast: Tyra Biosciences, Inc. Price Predictions for 2026-2027

Last close, 22 Sept 2026
$26
−0.31% on the day

The 14 Wall Street analysts covering Tyra Biosciences, Inc. hold a median 12-month price target of $52 — +101.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 21 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.8B
Ticker Nerd rank
32 / 100
Median analyst target
$52
Analysts covering
14
Revenue$0.0
Operating income−$49.0M
Net income−$45.6M
Free cash flow−$31.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.6%
1M
−1.8%
YTD
−2.7%
1Y
+98.4%
From 52W high
−35.4%
From 52W low
+103.9%
$13
$40
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TYRA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tyra Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Sept 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
79
Volatility
67
Value
54
Accruals
44
Issuance
42
Size
37
Quality
34
Revisions
34
Growth
27

Momentum (79): The shares have been drifting up relative to others.

Growth (27): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TYRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TYRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26TYRAHigh $59Median $52Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
13 Buy1 Hold0 Sell
Low $30Median $52High $59

The green dot is the last close — the median target sits +101.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Sept 2026HC Wainwright & Co.MaintainsBuy$45 → $30
10 Sept 2026WedbushReiteratesOutperform$53
4 Sept 2026HC Wainwright & Co.ReiteratesBuy$45
17 June 2026Jones TradingInitiatesBuy$56
17 June 2026Jones TradingInitiatesBuy—
10 June 2026B of A SecuritiesMaintainsBuy$37 → $42
10 June 2026B of A SecuritiesMaintainsBuy—
19 May 2026Wolfe ResearchInitiatesPeer Perform—
14 May 2026HC Wainwright & Co.ReiteratesBuy—
15 Apr 2026GuggenheimInitiatesBuy—
6 Apr 2026Canaccord GenuityInitiatesBuy—
20 Mar 2026Piper SandlerMaintainsOverweight—
24 Feb 2026Cantor FitzgeraldInitiatesOverweight—
17 Feb 2026HC Wainwright & Co.MaintainsBuy—
13 Feb 2026WedbushMaintainsOutperform—
3 Feb 2026JefferiesMaintainsBuy—
3 Feb 2026OppenheimerMaintainsOutperform—
28 Jan 2026BarclaysInitiatesOverweight—
23 Jan 2026Piper SandlerMaintainsOverweight—
16 Dec 2025WedbushMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TYRA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TYRA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Sept 2026, Tyra Biosciences, Inc. returned +98.4% against +17.2% for the S&P 500, dividends included.

TYRA vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26TYRAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TYRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
11
Fundamentals

Tyra Biosciences, Inc. (TYRA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−12.8×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
4.3×

Cheaper than 23% of US stocks

EV / EBITDA
−7.4×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−45.3%

Higher than 23% of US stocks

Return on assets
−28.5%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tyra Biosciences, Inc. (TYRA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tyra Biosciences, Inc. has a market value of $1.8B and an enterprise value of $1.2B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$148.6M.

  • Diluted earnings per share, trailing twelve months: $−2.40.

  • Free cash flow in the twelve months to 30 June 2026: −$109.9M.

  • Shares outstanding: 59.7M.

  • Trailing P/E: −12.8×; forward P/E: −9.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Tyra Biosciences, Inc. employs 87 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Sept 2026

Data provided by Twelve Data

Peers

TYRA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TYRATyra Biosciences, Inc.$1.8B
32
COAGHemab Therapeutics Holdings, Inc.$1.8B
1
STOKStoke Therapeutics, Inc.$1.7B
54
SEPNSepterna, Inc.$1.7B
90
NVAXNovavax, Inc.$1.7B
56
NTLAIntellia Therapeutics, Inc.$1.7B
52
MRVIMaravai Lifesciences Holdings, Inc.$1.8B
88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tyra Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TYRA news & analysis

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

PRNewsWire · 14 Sept 2026neutral

Tyra Biosciences announced the pricing of an underwritten offering of 9,079,000 shares of common stock at $22.03 per share, along with pre-funded warrants to purchase 9,078,529 shares at $22.029 per share, for approximately $400 million. The offering is being made to investors as part of a capital raise.

Why it matters — The offering provides Tyra with substantial new capital to fund its clinical-stage FGFR precision medicine programs, though it also expands the company's outstanding share count.

Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript

Seeking Alpha · 10 Sept 2026neutral

Tyra Biosciences discussed initial SURF302 results for its oral dabogratinib candidate in intermediate-risk non-muscle invasive bladder cancer, as covered in a Seeking Alpha transcript. The item reports on the company's presentation of these early findings.

Why it matters — A TYRA watcher would care because dabogratinib is a key pipeline candidate and early SURF302 data on intermediate-risk NMIBC could signal the drug's potential in a new indication.

Why Is Tyra Biosciences Stock Sinking Wednesday?

Benzinga · 9 Sept 2026negative

Tyra Biosciences stock traded lower Wednesday after the company shared initial results from its Phase 2 SURF302 trial of oral dabogratinib, which delivered clinical proof of concept and identified a 60 mg once-daily dose to support planned registrational studies.

Why it matters — TYRA watchers would track the market's reaction to the Phase 2 data and the selected dose, as it informs the path toward registrational studies.

Tyra Plummets To 10-Month Low On Mixed Bladder Cancer Results

Investors Business Daily · 9 Sept 2026negative

Tyra Biosciences stock fell to a 10-month low after the company reported mixed test results for its experimental bladder cancer treatment. The news drove shares sharply lower on Wednesday.

Why it matters — A TYRA watcher would care because mixed results for its key experimental bladder cancer treatment raise uncertainty about the drug's prospects and weighed heavily on the share price.

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress

Barrons · 9 Sept 2026negative

Tyra Biosciences' stock plunged 22% after its bladder cancer pill failed to impress in what appears to be a disappointing clinical result. The company, along with Johnson & Johnson, is pursuing its own approach to treating a common, early-stage form of bladder cancer.

Why it matters — TYRA watchers would care because a disappointing clinical outcome for the company's bladder cancer drug caused a significant share-price drop, signalling concerns about its pipeline prospects.

FAQ

Frequently asked questions about TYRA stock

What is the TYRA stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Tyra Biosciences, Inc. have a median 12-month price target of $52, with estimates ranging from $30 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TYRA stock a buy right now?

Of the 14 analysts covering Tyra Biosciences, Inc., 13 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tyra Biosciences, Inc. 32 out of 100 across roughly 4,600 US stocks as at 21 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TYRA?

As at 21 Sept 2026, Tyra Biosciences, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (79 of 100).

Will TYRA stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +101.4% from the last close, and Ticker Nerd's factor model ranks Tyra Biosciences, Inc. 32 out of 100 as at 21 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TYRA stock forecast for 2030?

No analyst covering Tyra Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TYRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $59 over the next 12 months.

How has TYRA stock performed over the past year?

Tyra Biosciences, Inc. returned +98.4% over the 12 months to 22 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tyra Biosciences, Inc. do?

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target fibroblast growth factor receptor (FGFR) biology.

What is the latest news on TYRA?

The most recent item we track (PRNewsWire, 14 Sept 2026): "Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants". Tyra Biosciences announced the pricing of an underwritten offering of 9,079,000 shares of common stock at $22.03 per share, along with pre-funded warrants to purchase 9,078,529 shares at $22.029 per share, for approximately $400 million. The offering is being made to investors as part of a capital raise.

Company

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target fibroblast growth factor receptor (FGFR) biology. The company’s core work centers on designing small-molecule therapies for genetically defined cancers and rare skeletal disorders, using its SNÅP platform to support structure-guided drug discovery and rapid optimization. Tyra Biosciences is advancing oral dabogratinib across urologic cancers and skeletal dysplasia programs, alongside other FGFR-targeted candidates in its pipeline. Its current business is built around clinical development, translational research, and precision oncology, with an emphasis on conditions where specific genetic alterations drive disease. Headquartered in Carlsbad, California, Tyra Biosciences operates as a focused biotechnology developer serving the oncology and rare disease markets.

CEO Dr. Todd Harris Ph.D. · 87 employees · United States · https://tyra.bio